“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”

“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”